4. Segment information

4. Segment information

In 2014, following the sale of the service division on 1 April 2014, the continuing operations related primarily to R&D activities. Consequently, there was one reportable segment as at 31 December 2014.

In 2015, the IFRS 8 threshold of 10% of the combined revenues, external and inter-segment, of all segments was met by the external and internal revenues reported by our fee-for-service business located in Croatia. Consequently, there are two reportable segments in 2015, R&D and fee-for-service business.

Segment information for the year 2015

(thousands of €)

R&D

Fee-For-Services

Inter-segment elimination

Group

Revenue

34,129

10,893

(5,459)

39,563

Other income

20,778

238

 

21,017

(1)

Unallocated expenses consist mainly of expenses for warrant plans under IFRS2

(2)

Cash and taxes are handled at the Group level and are therefore presented under unallocated (expenses) / income

Revenues & other income

54,907

11,131

(5,459)

60,579

 

 

 

 

 

Segment result

(82,024)

(2,690)

 

(84,713)

Unallocated expenses (1)

 

 

 

(4,731)

Operating loss

 

 

 

(89,444)

Financial (expenses) / income (2)

 

 

 

(30,184)

Result before tax

 

 

 

(119,627)

Incomes taxes (2)

 

 

 

1,218

Net loss from continuing operations

 

 

 

(118,410)

Net income from discontinued operations

 

 

 

Net income / loss (–)

 

 

 

(118,410)

Segment information for the year 2014

(thousands of €)

R&D

Fee-For-Services

Inter-segment elimination

Group

Revenue

65,642

7,809

(4,083)

69,368

Other income

20,437

217

 

20,653

(1)

Unallocated expenses consist mainly of expenses for warrant plans under IFRS2

(2)

Cash and taxes are handled at the Group level and are therefore presented under unallocated (expenses) / income

Revenues & other income

86,079

8,025

(4,083)

90,021

 

 

 

 

 

Segment result

(30,369)

(4,704)

 

(35,073)

Unallocated expenses (1)

 

 

 

(1,551)

Operating loss

 

 

 

(36,624)

Financial (expenses) / income (2)

 

 

 

1,424

Result before tax

 

 

 

(35,201)

Incomes taxes (2)

 

 

 

(2,103)

Net loss from continuing operations

 

 

 

(37,303)

Net income from discontinued operations

 

 

 

70,514

Net income / loss (–)

 

 

 

33,211

Geographical information

In 2015 our operations were located in Belgium, Croatia, France and The Netherlands.

In 2015 our top 10 customers represented 97% of the revenues. Our client base in 2015 and 2014 included six of the top 20 pharmaceutical companies in the world.

Following table summarizes our revenues by destination of customer:

 

As at 31 December

(thousands of €)

2015

2014

United States

17,077

31,100

Europe

22,446

38,169

Asia Pacific

40

100

Total revenues

39,563

69,368

Following table summarizes our revenues by major customers:

 

As at 31 December

 

2015

2014

 

(thousands of €)

%

(thousands of €)

%

AbbVie

29,870

75%

54,092

78%

Europe

13,640

34%

24,054

35%

United States

16,229

41%

30,038

43%

Janssen Pharmaceutica

566

1%

8,662

12%

Europe

112

0%

8,662

12%

United States

454

1%

 

 

Total revenues

30,436

77%

62,754

90%

Following table summarizes our revenues of the continuing operations by destination of our entity:

 

Year ended 31 December

(thousands of €)

2015

2014

Galapagos NV (Belgium)

34,082

65,448

Galapagos SASU (France)

25

108

Fidelta d.o.o. (Croatia)

5,440

3,726

Xenometrix, Inc. (United States)

16

86

Total revenues

39,563

69,368

In 2015, we held €68 million of non-current assets (€57 million in 2014) distributed as follows:

  • France: €29 million (€26 million in 2014)
  • Belgium: €30 million (€25 million in 2014)
  • Croatia: €5 million (€4 million in 2014)
  • The Netherlands: €4 million (€1 million in 2014)

The increase in non-current assets is explained by the increase in non-current R&D incentives receivables (see note 15).